Gamma butyrolactone (GBL) and gamma valerolactone (GVL): similarities and differences in their effects on the acoustic startle reflex and the conditioned enhancement of startle in the rat

Pharmacology, Biochemistry, and Behavior
Laureen J MarinettiRandall Commissaris

Abstract

Gamma butyrolactone (GBL) is metabolized to gamma hydroxybutyrate (GHB) in the body. GHB is a DEA Schedule 1 compound; GBL is a DEA List 1 chemical. Gamma valerolactone (GVL) is the 4-methyl analog of GBL; GVL is metabolized to 4-methyl-GHB; GVL is NOT metabolized to GBL or GHB. The effects of GBL (18.75-150 mg/kg), GVL (200-1600 mg/kg) or vehicle on the acoustic startle reflex (ASR), and the classically-conditioned enhancement of startle, the Startle Anticipated Potentiation of Startle (SAPS) response were studied in male rats. Both compounds produced a dose-dependent reduction of ASR, with GBL 5-7 times more potent than GVL. In contrast, GBL treatment significantly reduced SAPS at doses that exerted only moderate effects on ASR, whereas GVL exerted little or no effect on the SAPS, except at doses that produced pronounced reductions in Noise Alone ASR. In a second experiment, rats were tested for Noise Alone ASR behavior following treatment with a single mid-range dose of GBL (75 mg/kg), GVL (400mg/kg) or vehicle; immediately following startle testing the animals were sacrificed and their brains and blood were collected for determination of GHB, 4-methyl-GHB, GBL and GVL. GHB was found in measurable concentrations in all of th...Continue Reading

References

Mar 1, 1976·Pharmacology, Biochemistry, and Behavior·L A PohoreckyS L Jaffe
May 1, 1988·Journal of Medicinal Chemistry·J J BourguignonM Maitre
Dec 20, 1993·Behavioural Brain Research·M DavisM Kim
Sep 13, 2003·British Journal of Pharmacology·Christophe QuévaJan P Mattsson
Feb 1, 1965·Biochemical Pharmacology·R H ROTH, N J GIARMAN
Oct 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Lawrence P CarterCharles P France
May 1, 1951·Journal of Experimental Psychology·J S BROWNI E FARBER
Sep 1, 2005·European Journal of Pharmacology·Nikola DimitrijevicHari Manev
May 2, 2006·European Journal of Pharmacology·Lawrence P CarterCharles P France

❮ Previous
Next ❯

Citations

Jan 8, 2016·Medicinal Research Reviews·Michel MaitreAyikoe G Mensah-Nyagan
Jul 28, 2018·Journal of Molecular Modeling·Felippe M ColombariLuiz Carlos G Freitas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.